ABIVAX SA-ADR(NASDAQ:ABVX) stock News

ABVX Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Chartmill - Mentions: CYCC KMT OPEN BCLI ...

Curious about the stocks that are showing activity after the closing bell on Friday?

12 days ago - By: Chartmill - Mentions: CYCC GTI GAME CREG ...

Get insights into the top gainers and losers of Wednesday's pre-market session.

3 days ago - By: Benzinga - Mentions: INTC ALM SNV SRPT ...

Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session

3 days ago - By: Abivax

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

3 days ago - By: Abivax

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

4 days ago - By: Abivax

Abivax announces trading resumption of its ordinary shares on Euronext Paris

4 days ago - By: Abivax

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

4 days ago - By: Abivax

Abivax announces trading resumption of its ordinary shares on Euronext Paris

4 days ago - By: Abivax

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

4 days ago - By: Abivax

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

4 days ago - By: Abivax

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

4 days ago - By: Abivax

Abivax Announces Launch of Public Offering

4 days ago - By: Abivax

Abivax Announces Launch of Public Offering

4 days ago - By: Benzinga - Mentions: TMO TXN FI ANEB ...

Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views

5 days ago - By: Investor's Business Daily - Mentions: PFE LLY MRK

Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results

5 days ago - By: Abivax

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

2 months ago - By: Abivax

Abivax Announces Results of its June 6, 2025 Annual General Meeting

2 months ago - By: Abivax

Abivax Announces Results of its June 6, 2025 Annual General Meeting

2 months ago - By: Abivax

Abivax Presents First Quarter 2025 Financial Results

2 months ago - By: Abivax

Abivax Presents First Quarter 2025 Financial Results

3 months ago - By: Abivax

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

3 months ago - By: Abivax

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

3 months ago - By: Abivax

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

3 months ago - By: Abivax

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

3 months ago - By: Abivax

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

3 months ago - By: Abivax

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

4 months ago - By: Abivax

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

4 months ago - By: Abivax

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

4 months ago - By: Abivax

ABIVAX SA-ADR (ABVX) Stock News

ABVX Latest News, Press Relases and Analysis

Curious about the stocks that are showing activity after the closing bell on Friday?

Get insights into the top gainers and losers of Wednesday's pre-market session.

Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax Announces Launch of Public Offering

Abivax Announces Launch of Public Offering

Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views

Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Abivax Presents First Quarter 2025 Financial Results

Abivax Presents First Quarter 2025 Financial Results

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax Announces Full Year 2024 Financial Results